Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®
Voice
Description
Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (ZynlontaTM) for adults with relapsed or refractory large B-cell lymphoma.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education